(Q28575717)

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Differential expression of cell surface glycoproteins on various organ-derived microvascular endothelia and endothelial cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Effects of gonadal steroids on the growth of human pituitary adenomas in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Transient HTLV-I infection of a human glioma cell line following cell-free exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

The antiphospholipid syndrome: ten years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Monoclonal autoantibodies to cardiolipin derived from SLE mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

7 January 2021

Beta 2-glycoprotein I.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Effect of human T lymphotropic retrovirus-I exposure on cultured human glioma cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

The 1982 revised criteria for the classification of systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

A new player in the antiphospholipid syndrome: the beta 2 glycoprotein I cofactor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with a thrombosis-prone subset of patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6

Thrombogenicity of vascular cells. Comparison between endothelial cells isolated from different sources and smooth muscle cells and fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2898%2900027-6